Biotransformation of 5´-O-β-D-galactosyl-floxuridine by immobilized β-galactosidase from Kocuria rhizophila
5-fluorouracil-2’-deoxyriboside (FUdR), an antimetabolite known as floxuridine, is a halogenated nucleoside extensively used in the clinical treatment of colon carcinoma and hepatic metastases. This drug presents low bioavailability, thus requiring large doses and frequent administration, which lead...
| Autores: | , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2018 |
| País: | Argentina |
| Institución: | Consejo Nacional de Investigaciones Científicas y Técnicas |
| Repositorio: | CONICET Digital (CONICET) |
| Idioma: | inglés |
| OAI Identifier: | oai:ri.conicet.gov.ar:11336/98195 |
| Acceso en línea: | http://hdl.handle.net/11336/98195 |
| Access Level: | acceso abierto |
| Palabra clave: | Enzyme stabilization Floxuridine Galactosylation Biocatalysis https://purl.org/becyt/ford/1.6 https://purl.org/becyt/ford/1 |
| Sumario: | 5-fluorouracil-2’-deoxyriboside (FUdR), an antimetabolite known as floxuridine, is a halogenated nucleoside extensively used in the clinical treatment of colon carcinoma and hepatic metastases. This drug presents low bioavailability, thus requiring large doses and frequent administration, which leads to long-lasting and severe side effects in clinical practice. In order to overcome this problem, galactosylated nucleoside analogues were obtained using immobilized β-galactosidase in Ca-alginate with yields of 80% at only 7 h. Additionally, the obtained biocatalyst was stable for 6 months in storage conditions (4 °C) and could be reused at least 16 times without loss of its activity at 30 °C. This work describes for the first time an efficient, eco-compatible and simple bioprocess for obtaining 5´-O-β-D-galactosyl-floxuridine using an immobilized biocatalyst. |
|---|